About this episode:

Respiratory syncytial virus can be particularly dangerous for older adults and infants and this year, for the first time, there are three approved and readily available products to help prevent severe disease: A vaccine for pregnant women and people over age 65, and an antibody treatment for infants born during RSV season. In this episode: all about these products and the promise they show for dramatically reducing the number of hospitalizations and deaths from RSV this year.

Guests:

Dr. Georgina Peacock is the director of the Immunization Services Division in the National Center on Immunization and Respiratory Diseases at the CDC.

Host:

Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department.

Show links and related content:

• Surveillance of RSV—CDC

• Why So Many Babies Didn't Get RSV Vaccines This Winter—Public Health On Call (February, 2024)

Contact us:

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

Follow us:

• @‌PublicHealthPod on X

• @‌JohnsHopkinsSPH on Instagram

• @‌JohnsHopkinsSPH on Facebook

• @‌PublicHealthOnCall on YouTube

• Here's our RSS feed